Emyria Limited (ASX:EMD)

Australia flag Australia · Delayed Price · Currency is AUD
0.0470
-0.0010 (-2.08%)
At close: Mar 6, 2026
46.88%
Market Cap 37.91M
Revenue (ttm) 2.29M
Net Income (ttm) -4.55M
Shares Out 806.56M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,303,516
Average Volume 1,004,236
Open 0.0470
Previous Close 0.0480
Day's Range 0.0440 - 0.0480
52-Week Range 0.0210 - 0.0780
Beta 0.05
RSI 33.82
Earnings Date May 27, 2026

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnersh... [Read more]

Sector Healthcare
Founded 2018
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol EMD
Full Company Profile

Financial Performance

In fiscal year 2025, Emyria's revenue was 1.39 million, a decrease of -36.68% compared to the previous year's 2.20 million. Losses were -3.14 million, -72.57% less than in 2024.

Financial Statements

News

There is no news available yet.